ClinicalTrials.gg
RecruitingNCT05080556ACTOvUpdated Apr 12, 2024

Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer

A Phase 2 interventional study of Carboplatin in Ovarian Cancer, Relapsed Ovarian Cancer and Fallopian Tube Cancer, sponsored by University College, London. Recruiting at 1 site in United Kingdom. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-12.

Primary conditionCarcinoma, EndometrioidRegistry: Ovarian NeoplasmsReclassifiedWhy we changed it
Registry
Ovarian Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Carcinoma, Endometrioid
Why
  1. The study's listed conditions name Carcinoma, Endometrioid, a narrower term within Ovarian Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University College, London · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started May 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

ACTOv will compare standard 3-weekly carboplatin (AUC5), to carboplatin delivered according to an AT regimen. The AT regimen will modify carboplatin dose according to changes in the clinical-standard serum biomarker CA125 as a proxy measure of total tumour burden and an individual patient's response to the most recent chemotherapy treatment. AT could prolong sensitivity to carboplatin and extend tumour control, while simultaneously reducing chemotherapy dose and drug-induced toxicity. Carboplatin is a low cost and low toxicity drug that has an enduring and central role in ovarian cancer treatment.

02

Conditions studied

  • Ovarian Cancer
  • Relapsed Ovarian Cancer
  • Fallopian Tube Cancer
  • Peritoneal Cancer
  • Endometrioid Carcinoma
  • High Grade Serous Carcinoma
  • Ovary Cancer

Browse trials for

03

In context

Carcinoma, Endometrioid Reclassified

46 studies on the registry are indexed under Carcinoma, Endometrioid; 11 are open to participants now.

This study's planned enrollment of 80 is close to the median of 79 across 36 interventional studies indexed under Carcinoma, Endometrioid.

Browse Carcinoma, Endometrioid studies →

Lead sponsor

University College, London is the lead sponsor of 651 studies on the registry; 149 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.

Compared within Carcinoma, Endometrioid, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Ovarian Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female patients aged ≥18 years
  2. performance status 0-2
  3. proven diagnosis of high grade serous or high grade endometrioid carcinoma of the ovary, fallopian tube or peritoneum
  4. Most recent regimen must have included platinum (cisplatin or carboplatin)
  5. Must have previously received a PARP inhibitor
    1. Must have responded to most recent platinum treatment by CT or MRI or by GCIG CA125 response criteria
  6. Pre-trial CT or MRI-confirmed disease relapse ≥ 6 months after day 1 of the last cycle of platinum-containing chemotherapy (cisplatin or carboplatin) and requiring treatment with further platinum-based chemotherapy
  7. by v1.1 on a CT scan conducted within 28 days prior to randomisation (Patient with non-measurable disease could be eligible if they meet GCIG CA125 progression criteria)
  8. CA125 ≥ 100iU/l at screening
  9. Agree to provide additional research blood samples at the same time as blood draws prior to each carboplatin treatment, 6-weekly during surveillance and at 12- weekly follow-up visit
  10. Expected to be able to commence treatment within 28 days post randomisation
  11. Adequate bone marrow function
  12. Adequate liver function
  13. Adequate renal function
  14. or women of (WOCBP) must agree to have an urine or serum pregnancy test at screening for evidence of non-childbearing status and prior to trial treatment and use adequate for duration of trial
  15. Willing and able to give consent and able to comply with treatment and follow up schedule

Exclusion criteria

Exclusion Criteria:

  1. Non-epithelial ovarian cancer, carcinosarcoma, low-grade serous and endometrioid carcinomas, mucinous \& clear-cell carcinomas
  2. Patients requiring treatment with combination chemotherapy regimens
  3. Patients with a known to carboplatin
  4. Persisting ≥ grade 2 v5 adverse events/ toxicity (except alopecia and neuropathy) from previous anti-cancer treatment.
  5. Treatment with any other agent, or participation in another interventional clinical trial within 28 days prior to randomisation.
  6. Major surgery within 14 days before anticipated start of treatment and patients must have recovered from any effects of major surgery.
  7. Evidence of any other disease, metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that the use of an investigation drug or puts the patients at high risk for treatment-related complications.
  8. Other psychological, psychiatric, social or medical condition, physical examination finding or a laboratory abnormality that the Investigator considers would make the patient a poor trial candidate or could interfere with protocol compliance or the interpretation of trial results.
  9. treated within the last 5 years except: adequately treated non-melanoma skin cancer, curatively treated in situ cancer of the cervix, ductal carcinoma in situ (DCIS) of the breast, Stage 1, grade 1 endometrial carcinoma.
  10. Patients with symptomatic uncontrolled brain or meningeal . A scan to confirm the absence of is not required. The patient can receive a stable dose of before and during the study as long as these were started at least 4 weeks prior to treatment.
  11. Patients with spinal cord compression unless considered to have received definitive treatment for this and evidence of clinically stable disease for 28 days prior to randomisation.
  12. Pregnant or breast-feeding women are excluded. Women of will be excluded unless effective methods of are used from signing of the , throughout the period of taking study treatment and for at least 6 months after last dose of trial drug(s).
  13. Inability to attend or comply with treatment or follow-up scheduling.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Active comparator
    Arm 1 (control) - standard dosing carboplatin

    Arm 1 (Standard Dosing): Carboplatin AUC5 based on nuclear medicine renal clearance.

    Drug: Carboplatin

  • Experimental
    Arm 2 (experimental) - adaptive therapy carboplatin according to CA125

    Arm 2 (Adaptive Therapy): Carboplatin dose will be calculated according to the CA125 value.

    Drug: Carboplatin

Interventions

  • Treatment in both arms will be administered intravenously (IV) every 21 days (q21D) and for a maximum of 6 cycles in Arm 1 and 12 cycles in Arm 2.

06

What researchers measure

Primary outcomes

  1. Modified Progression Free Survival (mPFS)

    Measured from the date of randomisation to the date of objective progression (investigator assessed using RECIST v1.1) but comparing CT scans to the baseline CT rather than the radiological nadir), clinical progression or death from any cause (in the absence of progression)

    Time frame: From the date of randomisation until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 4 years.

Secondary outcomes

  1. Acceptability (1/2)

    the number of eligible patients approached who accept randomisation and continue to receive treatment

    Time frame: From the date of randomisation to the first dose of treatment (within 28 days from randomisation)received by patient. Measured as the number of patients approached who accept randomisation.

  2. Acceptability (2/2)

    the proportion of eligible patients approached who accept randomisation and continue to receive treatment

    Time frame: From the date of randomisation to the first dose of treatment (within 28 days from randomisation)received by patient. Measured as the percent of patients approached who accept randomisation.

  3. Deliverability (1/2)

    the number of treatment cycles that are delivered as per protocol, described by trial arm

    Time frame: Measured as the number of treatment cycles that are delivered as per protocol, described by trial arm (maximum of 6 cycles in control arm and 12 in experimental arm, approx.. 18 weeks and 36 weeks respectively). Treatment delays, reductions and omissions

  4. Deliverability (2/2)

    the proportion of treatment cycles that are delivered as per protocol, described by trial arm

    Time frame: Measured as the number of treatment cycles that are delivered as per protocol, described by trial arm (maximum of 6 cycles in control arm and 12 in experimental arm, approx.. 18 weeks and 36 weeks respectively). Treatment delays, reductions and omissions

  5. Compliance

    total cumulative carboplatin dose will be calculated for each patient over time on treatment, and described by trial arm

    Time frame: Total cumulative carboplatin dose will be calculated for each patient over time on treatment (max. of 6 cycles in control arm and 12 cycles in experimental arm, approximately 18 weeks and 36 weeks respectively

  6. Adverse events (1/2)

    adverse events will be categorised using the NCI Common Terminology Criteria for Adverse Events (CTCAE), version 5. The number of patients who suffer a grade 3 or 4 toxicity at any time, and the maximum grade of toxicity for each adverse event term, will be described by trial arm

    Time frame: Adverse events will be reported between informed consent and 30 calendar days post last IMP (i.e. max. of 6 cycles in control arm and 12 cycles in experimental arm, approximately 30 days after 18 weeks or 36 weeks respectively)

  7. Adverse events (2/2)

    adverse events will be categorised using the NCI Common Terminology Criteria for Adverse Events (CTCAE), version 5. The percentage of patients who suffer a grade 3 or 4 toxicity at any time, and the maximum grade of toxicity for each adverse event term, will be described by trial arm

    Time frame: Adverse events will be reported between informed consent and 30 calendar days post last IMP (i.e. max. of 6 cycles in control arm and 12 cycles in experimental arm, approximately 30 days after 18 weeks or 36 weeks respectively)

  8. Quality of life (1/2) - EORTC questionnaire (assessing the quality of life of patients with ovarian cancer)

    measured using European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC questionnaires): Quality of Life cancer 30 (QLQ-C30) (suitable for all cancer types) and Qualify of life questionnaire (QLQ-OV28 (ovarian cancer-specific)) in scale of 4 (1 is not very much and 4 very much)

    Time frame: At baseline, during treatment and follow up until the first documented progression or date of death (estimate 6 or 12 months but can be up to 4 years)

  9. Quality of life (2/2) - EQ-5D ((mobility, self-care, usual activities, pain/discomfort, anxiety/depression, a single summary index and a visual analogue scale)

    measured using European Quality of life questionnaire five dimensions (EQ-5D (descriptive profile of health state)) in scale of 5 (1 is no problem and 5 is extreme problem)

    Time frame: At baseline, during treatment and follow up until the first documented progression or date of death (estimate 6 or 12 months but can be up to 4 years)

  10. Fear of progression

    measured using Fear of progression questionnaire (FOP-Q SF) in scale of 1 to 5 where 1 is never and 5 is very often

    Time frame: At baseline, during treatment and follow up until the first documented progression or date of death (estimate 6 or 12 months but can be up to 4 years)

  11. CA125

    measured at baseline, 3-weekly during treatment, 6-weekly during surveillance and 12-weekly during follow-up

    Time frame: Measured at baseline, 3 weekly during treatment, 6-weekly during surveillance and 12-weekly during follow-up, through study completion, an average of 1 year.

  12. Further treatment (1/3)

    of patients who progress will be described by trial arm including the time-to-next treatment (measured from randomisation)

    Time frame: Additional treatment of patients who progress will be described by trial arm, this will include the time-to-next treatment (measured from randomisation).

  13. Further treatment (2/3)

    of patients who progress will be described by trial arm including the time treatment received (measured from randomisation)

    Time frame: Additional treatment of patients who progress will be described by trial arm, this will include the time treatment received (measured from randomisation)

  14. Further treatment (3/3)

    of patients who progress will be described by trial arm including the time response to this treatment (measured from randomisation)

    Time frame: Additional treatment of patients who progress will be described by trial arm, this will include the time response to this treatment (measured from randomisation)

  15. Overall survival

    measured from the date of randomisation to the date of death from any cause. Patients who are event-free will be censored at the date last seen

    Time frame: Measured from the date of randomisation to the date of death from any cause, censored at the date last seen (estimate 2 years but can be up to 4 years)

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2023 (actual). Primary completion is estimated for Nov 2026, 41 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2021
First posted
Oct 15, 2021
StartActual
May 24, 2023
Primary completionEst.
Nov 1, 2026
CompletionEst.
Nov 1, 2027
Last update
Apr 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05080556
Collaborators
Anticancer Fund, Belgium, JP Moulton Charitable Foundation, Barts & The London NHS Trust
Responsible party
Sponsor
First posted
Oct 15, 2021
Start date
May 24, 2023
Primary completion
Nov 1, 2026 (estimated)
Completion
Nov 1, 2027 (estimated)
Last update
Apr 12, 2024

Study contacts

ACTOv Trial Coordinator
Contact
ctc.actov@ucl.ac.uk
02076794466

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Carboplatin

Start the discussion